ReviewAntibiotics (Basel, Switzerland)2021
Bacterial Nosocomial Infections: Multidrug Resistance as a Trigger for the Development of Novel Antimicrobials.
Review in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Multitarget Antibacterial Activity of Novel Aryl-Urea Derivatives Against Vancomycin- and Carbapenem-Resistant Nosocomial Pathogens.Current microbiology · 2026Article
- Staphylococcus capitis strain producing dual bacteriocins, capidermicin and micrococcin P1, shows broad-spectrum antimicrobial activity.Scientific reports · 2026Article
- Root cause analysis of the challenges to sustain effectiveness of clinical pharmacist-driven antimicrobial stewardship in a Chinese Tertiary Hospital.Frontiers in public health · 2026Article
- Colonization of the gut byFrontiers in cellular and infection microbiology · 2026Article
- [Beta-lactams and beta-lactamase inhibitors-current developments].Innere Medizin (Heidelberg, Germany) · 2025Review
- Beyond Antibiotics: Repurposing Non-Antibiotic Drugs as Novel Antibacterial Agents to Combat Resistance.International journal of molecular sciences · 2025Review
- Mortality Risk of Colistin vs. Non-Colistin Use in Cancer Patients with Multidrug-Resistant Gram-Negative Bacterial Infections: Stratified by Resistance Profile and Concomitant Medications.Medicina (Kaunas, Lithuania) · 2025Article
- Article
- Equine Distal Limb Wounds: Economic Impact and Short-Term Prognosis of Non-Synovial Versus Synovial Lesions in Southern Germany.Veterinary sciences · 2025Article
- Synergistic Antibiofilm Effects of Chestnut and Linden Honey with Lavender Essential Oil Against Multidrug-Resistant Otitis Media Pathogens.Antibiotics (Basel, Switzerland) · 2025Article
- Phytochemical analysis and evaluation of the antibacterial and antibiotic potentiation activities of the aqueous extract ofPharmaceutical science advances · 2024Article
- Synergistic efficacy of ZnO quantum dots, Ag NPs, and nitazoxanide composite against multidrug-resistant human pathogens as new trend of revolutionizing antimicrobial treatment.Discover nano · 2024Article
- FTY720 Reduces the Biomass of Biofilms inAntibiotics (Basel, Switzerland) · 2024Article
- Opportunities and challenges of microbial siderophores in the medical field.Applied microbiology and biotechnology · 2023Review
- Repurposing Selamectin as an Antimicrobial Drug against Hospital-AcquiredMicroorganisms · 2023Article
- Membrane Vesicles Derived from Gut Microbiota and Probiotics: Cutting-Edge Therapeutic Approaches for Multidrug-Resistant Superbugs Linked to Neurological Anomalies.Pharmaceutics · 2022Review
- Chemical Barrier Proteins in Human Body Fluids.Biomedicines · 2022Review
- Recent Advances in the Use of Molecular Methods for the Diagnosis of Bacterial Infections.Pathogens (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Nosocomial bacterial infections are associated with high morbidity and mortality, posing a huge burden to healthcare systems worldwide. The ongoing COVID-19 pandemic, with the raised hospitalization of patients and the increased use of antimicrobial agents, boosted the emergence of difficult-to-treat multidrug-resistant (MDR) bacteria in hospital settings. Therefore, current available antibiotic treatments often have limited or no efficacy against nosocomial bacterial infections, and novel therapeutic approaches need to be considered. In this review, we analyze current antibacterial alternatives under investigation, focusing on metal-based complexes, antimicrobial peptides, and antisense antimicrobial therapeutics. The association of new compounds with older, commercially available antibiotics and the repurposing of existing drugs are also revised in this work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.